Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/171258
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Cai, Rong | - |
dc.contributor.author | Zhang, Yu | - |
dc.contributor.author | Simmering, Jacob E. | - |
dc.contributor.author | Schultz, Jordan L. | - |
dc.contributor.author | Li, Yuhong | - |
dc.contributor.author | Fernández Carasa, Irene | - |
dc.contributor.author | Consiglio, Antonella | - |
dc.contributor.author | Raya Chamorro, Ángel | - |
dc.contributor.author | Polgreen, Philip M. | - |
dc.contributor.author | Narayanan, Nandakumar S. | - |
dc.contributor.author | Yuan, Yanpeng | - |
dc.contributor.author | Chen, Zhiguo | - |
dc.contributor.author | Su, Wenting | - |
dc.contributor.author | Han, Yanping | - |
dc.contributor.author | Zhao, Chunyue | - |
dc.contributor.author | Gao, Lifang | - |
dc.contributor.author | Ji, Xunming | - |
dc.contributor.author | Welsh, Michael J. | - |
dc.contributor.author | Li, Lei | - |
dc.date.accessioned | 2020-10-15T10:32:43Z | - |
dc.date.available | 2020-10-15T10:32:43Z | - |
dc.date.issued | 2019-10-01 | - |
dc.identifier.issn | 0021-9738 | - |
dc.identifier.uri | http://hdl.handle.net/2445/171258 | - |
dc.description.abstract | Parkinson's disease (PD) is a common neurodegenerative disease that lacks therapies to prevent progressive neurodegeneration. Impaired energy metabolism and reduced ATP levels are common features of PD. Previous studies revealed that terazosin (TZ) enhances the activity of phosphoglycerate kinase 1 (PGK1), thereby stimulating glycolysis and increasing cellular ATP levels. Therefore, we asked whether enhancement of PGK1 activity would change the course of PD. In toxin-induced and genetic PD models in mice, rats, flies, and induced pluripotent stem cells, TZ increased brain ATP levels and slowed or prevented neuron loss. The drug increased dopamine levels and partially restored motor function. Because TZ is prescribed clinically, we also interrogated 2 distinct human databases. We found slower disease progression, decreased PD-related complications, and a reduced frequency of PD diagnoses in individuals taking TZ and related drugs. These findings suggest that enhancing PGK1 activity and increasing glycolysis may slow neurodegeneration in PD. | - |
dc.format.extent | 11 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | American Society for Clinical Investigation | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1172/JCI129987 | - |
dc.relation.ispartof | Journal of Clinical Investigation, 2019, vol. 129, num. 10, p. 4539-4549 | - |
dc.relation.uri | https://doi.org/10.1172/JCI129987 | - |
dc.rights | (c) American Society for Clinical Investigation, 2019 | - |
dc.source | Articles publicats en revistes (Patologia i Terapèutica Experimental) | - |
dc.subject.classification | Malaltia de Parkinson | - |
dc.subject.classification | Malalties neurodegeneratives | - |
dc.subject.other | Parkinson's disease | - |
dc.subject.other | Neurodegenerative Diseases | - |
dc.title | Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 701890 | - |
dc.date.updated | 2020-10-15T10:32:43Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 31524631 | - |
Appears in Collections: | Articles publicats en revistes (Patologia i Terapèutica Experimental) Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
701890.pdf | 4.33 MB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.